Your Cart (0)
Add subscriptions to receive a discount
Frequently Bought With
8 MINUTE READ
12 CITATIONS
Vaginal Dryness, Explained
Vaginal Dryness, Explained
No more suffering in silence. Vaginal dryness is real, common, and treatable. Here’s how to get the relief you deserve.

Written by:

Team Biolae

Medically reviewed by:

Dr. Madison Davies

Jump to:

THE BIG PICTURE

Vaginal dryness during perimenopause and menopause is not a personal failing or a problem to push through. It is what happens when oestrogen falls and the tissue that depends on it loses elasticity, moisture, and infection resistance. Up to 50% of postmenopausal women experience symptoms of vaginal dryness, climbing to 80% in women over 651. Doctors call the full picture genitourinary syndrome of menopause (GSM): a cluster of vaginal, vulvar, and urinary symptoms that share one underlying cause.

The frustrating part is how rarely it gets treated. Fewer than 7% of women with GSM receive effective treatment2, which means the majority quietly carry it and assume this is just what menopause looks like. This guide explains what is physiologically happening, why symptoms tend to get worse over time, the full range of treatments that work, and how to raise the conversation with your GP without feeling embarrassed.

01

What Is Actually Happening to the Tissue

Vaginal dryness is the most visible symptom of a broader condition: genitourinary syndrome of menopause (GSM), previously called vulvovaginal atrophy. GSM is the medical term for the changes to vaginal, vulvar, and urinary tissue that follow declining oestrogen.3

What changes inside the tissue:

  • Vaginal walls thin. The lining (epithelium) loses cell layers and becomes more fragile.
  • Elasticity and rugae are lost. The folds that allowed the vagina to stretch comfortably flatten out.
  • Blood flow decreases. Less perfusion means less natural lubrication and slower healing.
  • pH rises. Healthy vaginal pH sits at 3.5–4.5. In GSM it shifts toward 5–7, which favours infection-causing bacteria.4
  • The microbiome shifts. Lactobacillus dominance drops, and overgrowth of other organisms becomes more likely.5
  • Urethral and bladder tissue also thin. This is why urinary symptoms travel with vaginal ones.
Diagram of vaginal tissue thinning before and after menopause: left panel shows a high-oestrogen environment with thick, moist vaginal lining and high blood flow; right panel shows declining oestrogen with thin, dry vaginal lining and decreased blood flow.

This is a tissue response to oestrogen withdrawal, not damage. The cells that depended on oestrogen to stay plump, blood-rich, and lubricated cannot do their job without it.

Importantly, GSM tends to get worse over time without treatment. Unlike hot flushes, which often peak and then settle, genital and urinary symptoms typically progress as oestrogen stays low for years. This is one of the strongest reasons earlier treatment produces better outcomes.

02

Why Menopause Causes It

Oestrogen receptors are embedded throughout the vagina, vulva, urethra, bladder, and pelvic floor.6 During reproductive years, those receptors keep tissue thick, elastic, well-perfused, and lubricated. As oestrogen falls in late perimenopause and postmenopause, receptor activity drops, and the tissue changes accordingly.

The decline does not happen all at once. In late perimenopause, oestrogen fluctuates wildly before its final fall. Some women notice the first signs of dryness during this phase, often without connecting it to their hormones. After the final menstrual period, oestrogen stays low, and symptoms typically progress for several years before stabilising at a new, lower baseline.

The full set of structures that lose oestrogen support:

  • The vaginal lining (epithelium) and walls
  • The vulvar skin, labia, and clitoris
  • The urethra and bladder trigone
  • The pelvic floor muscles
  • The cervix and lower uterus

This is why GSM produces such a wide range of symptoms beyond just dryness, from painful sex to frequent urinary tract infections to changes in vaginal discharge.

03

How Common It Really Is (and Why So Few Women Get Help)

The prevalence numbers are striking. Around half of postmenopausal women report GSM symptoms within five years of their final period, and three-quarters report them within ten years.1

Postmenopausal vaginal dryness statistics: over 50% of postmenopausal women experience symptoms, up to 80% for women aged 65 and older, yet less than 7% receive treatment.

The landmark REVIVE survey of 3,046 postmenopausal women found that only about 7% had ever used prescription treatment for GSM, and only around half had ever discussed vaginal symptoms with a healthcare provider.2 That is one of the widest treatment gaps in women's health.

The reasons women consistently give:

  • Assumed it was a normal, untreatable part of ageing
  • Embarrassment about discussing vaginal or vulvar symptoms
  • Did not realise effective treatments existed
  • Were told to "just use lubricant" and left without follow-up

GSM is medically well-characterised, the treatments are well-studied, and the outcomes for women who get treated are genuinely good. The barriers are almost entirely awareness and access, not biology.

04

The Symptoms (and Why It Is More Than Dryness)

GSM produces three clusters of symptoms.7

Vaginal and vulvar

  • Vaginal dryness, burning, or itching
  • Vulvar irritation or soreness
  • Loss of elasticity making penetration uncomfortable
  • Tissue thinning, visible on examination
  • Changes to vaginal discharge, typically less of it. If discharge changes in colour, smell, or consistency, read Menopausal Vaginal Discharge: What's Normal, What's Not for what to watch for.

Sexual

  • Painful sex (dyspareunia), the most common reason women seek treatment
  • Reduced arousal and sensation
  • Bleeding or spotting after intercourse
  • Reduced sex drive, often a downstream effect of pain rather than a separate libido problem

Urinary

  • Recurrent urinary tract infections
  • Urgency and frequency
  • Burning with urination, sometimes mistaken for UTI even when no infection is present
  • Mild urinary incontinence

If urinary symptoms are leading the picture, ask your GP specifically about GSM. Recurrent UTIs in postmenopausal women are often a GSM symptom, and treating the underlying tissue change reduces the infections.8

05

When to See Your GP

The single most useful thing you can do is stop waiting. The longer GSM goes untreated, the more tissue changes consolidate, and the harder symptoms become to fully reverse.9 Early treatment in the one-to-three years after the final period gives the best outcomes.

When to make the appointment

  • Dryness is interfering with daily comfort (sitting, walking, urinating)
  • Sex has become painful or you are avoiding it because of discomfort
  • Recurring UTIs or urinary symptoms with no clear cause
  • Any unusual bleeding or discharge (always worth checking)
  • Lubricant alone is not enough

How to bring it up

Naming the condition makes the conversation move faster. Saying "I think I have GSM" or "I have menopausal vaginal symptoms" tells your GP exactly where to start. Australian GPs are increasingly well-trained in menopause, particularly since the introduction of the Medicare menopause health check.

Own Your Menopause Appointment: 5 Tips from a GP walks through how to prepare so you actually leave with answers and a treatment plan, not another referral.

What to expect

  • A history conversation about symptoms, duration, and impact
  • A brief vaginal examination, which is used to confirm GSM and rule out other causes (infection, dermatoses)
  • A discussion of treatment options based on your medical history
  • A follow-up plan to assess whether the chosen treatment is working

If your GP is dismissive or unwilling to discuss treatment options beyond a lubricant, ask for a referral to a menopause specialist or another GP with menopause training. GSM is a known, treatable condition. You should not have to argue for treatment.

06

The Treatments You Will Hear About

This is a high-level overview of the main treatment categories. Each one has a dedicated Biolae article that goes deeper.

Lubricants

Used for immediate relief during sex. Water-based for everyday use and condom compatibility; silicone for longer-lasting slip. Lubricants do not treat the underlying tissue change. They reduce friction in the moment.

Vaginal moisturisers

Used 2–3 times per week (not just before sex) to hydrate vaginal tissue over time. Hyaluronic acid–based moisturisers can be as effective as low-dose vaginal oestrogen for many women.10 The full breakdown of which products work, and how to use them, is in What Helps with Vaginal Dryness?.

Hyaluronic acid suppositories

A newer non-hormonal option with growing trial evidence. For when and how to use them, and how they compare to vaginal oestrogen, see Does Hyaluronic Acid for Vaginal Dryness Really Work?.

How hyaluronic acid treats vaginal dryness, in three steps: Step 1, hyaluronic acid attracts moisture; Step 2, forms a protective barrier to prevent dryness; Step 3, promotes healing and tissue elasticity.

Local vaginal oestrogen

Low-dose oestrogen delivered as a cream, tablet, ring, or pessary. Acts locally on vaginal tissue with minimal systemic absorption.11 This is the most-studied and most-effective treatment for moderate-to-severe GSM. It is safe for most women, including many with a personal history of breast cancer (with their oncologist's input).

Systemic Menopausal Hormone Therapy (MHT)

Full-body hormone therapy treats GSM alongside hot flushes, sleep, mood, and bone symptoms. Considered when menopausal symptoms extend well beyond GSM. Discuss with your GP whether the benefits outweigh the risks in your specific case. The Australasian Menopause Society publishes plain-English guidance on who is and is not a candidate.

Lifestyle

Regular sexual activity (with adequate lubrication) maintains blood flow to the area. Avoiding irritants such as scented soaps, internal washes, douches, and harsh detergents reduces inflammation. Quitting smoking helps blood flow and oestrogen metabolism.

What does not work

Oral collagen supplements for vaginal tissue, "feminine wipes", coconut oil as a daily internal moisturiser (it can disrupt the microbiome), and pelvic floor exercises alone are all popularly recommended but lack evidence for treating GSM. They may have other benefits, but they do not address the tissue change.

07

Treatment timing matters more than most women are told

The earlier you start treatment, the more fully the tissue responds. Women who begin local vaginal oestrogen or hyaluronic acid in the first year or two after symptoms appear often see complete resolution within 8–12 weeks.12 Women who wait five years or more can still see significant improvement, but the response is usually slower and partial.

This is the reason GSM is not a "wait and see" condition. It is a progressive tissue change with a clearly defined treatment response window. Almost every woman who pursues treatment within that window gets meaningful relief. Many return to fully comfortable daily life and pain-free sex.

The barriers are awareness and willingness to bring it up, not the biology. If you are reading this and recognising your own experience, the next step is the GP appointment. Mention GSM by name. Ask about both non-hormonal and hormonal options. There is no medal for putting up with discomfort.

EDITORIAL STANDARDS
Biolae’s commitment to informed support

At Biolae, we’re here to support women through every stage of hormonal change with science-backed care, no judgment, and no guesswork. We believe education plays a powerful role in helping you understand what’s happening in your body and how to care for it.


Our content is guided by a commitment to clarity, trust, and evidence. Everything we share is reviewed for accuracy and informed by the latest clinical research and expert insight — so you can feel confident in every step you take with us.

References:
  1. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi:10.1097/GME.0000000000000329
  2. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. Journal of Sexual Medicine. 2013;10(7):1790–1799. doi:10.1111/jsm.12190
  3. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609
  4. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21(5):450–458. doi:10.1097/GME.0b013e3182a4690b
  5. Mitchell CM, Srinivasan S, Zhan X, et al. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause. 2017;24(10):1160–1166.
  6. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clinic Proceedings. 2017;92(12):1842–1849. doi:10.1016/j.mayocp.2017.08.019
  7. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3–9. doi:10.3109/13697137.2013.871696
  8. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102
  9. RACGP. Genitourinary syndrome of menopause. Australian Family Physician. 2017;46(7):481–484.
  10. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas. 2005;50(2):98–104.
  11. Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Internal Medicine. 2018;178(5):681–690. doi:10.1001/jamainternmed.2018.0116
  12. Australasian Menopause Society. Genitourinary symptoms of menopause information sheet. 2024. menopause.org.au